Helsinn attends 4th Annual Sino-Swiss Business Awards
Lugano, Switzerland, November 7, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, attended the 4th Annual Sino-Swiss Business Awards last Friday 1st November in Beijing, where its subsidiary, Helsinn Pharmaceuticals (Beijing) Co. Ltd., was shortlisted for the Business Award for Innovation and Creative Industries.
The Sino-Swiss Business Awards are organized by the Swiss Chinese Chamber of Commerce (SwissCham Beijing), this year in partnership with swissnex China, Switzerland Tourism and the Swiss Embassy. It took place during the Swiss Winter Festival at the Four Seasons Beijing hotel.
Hans P. Schmid, Chairman, Helsinn Pharmaceuticals (Beijing): “Since 2012, when Helsinn started operations in China, we have been committed to helping improve the lives of patients with cancer in China. To achieve this goal we will continue to bring our innovative pharmaceutical products to China and will expand our presence here. We are therefore honoured to have been nominated at this year’s Sino-Swiss Business Award for Innovation and Creative Industries in recognition of our efforts. The event was an invaluable opportunity to deepen relationships with other healthcare and business leaders in China, and whom we look forward to working with in the future.”
END
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.
To learn more about Helsinn Group please visit www.helsinn.com
For more information:
Helsinn Group Media Contact
Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo
Attachment
